← Back to list
Coverage of GLP-1s for Tufts Health RITogether members
Act
by Sep 30, 2026
Effective date
Oct 1, 2026
Identified
Sep 3, 2026
Summary
Effective October 1, 2026, Tufts Health RITogether (Rhode Island Medicaid) will no longer cover GLP-1 medications when prescribed solely for weight loss, including Saxenda, Wegovy, Zepbound, and Foundayo. However, Wegovy and Zepbound remain covered for specific FDA-approved indications (cardiovascular risk reduction, MASH with advanced fibrosis, and moderate-to-severe sleep apnea). GLP-1s approved for type 2 diabetes treatment will continue to be covered. All existing prior authorizations for weight-loss use will be end-dated by September 30, 2026, and affected members will be notified.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
Get Harvard Pilgrim Health Care alertsPolicy Monitoring is free. No card required.
What to do
by Sep 30, 2026 · 7 steps
01Billing and clinical teams must audit all active Tufts Health RITogether prior authorizations for GLP-1 medications to identify which are for weight-loss indication only.
02For weight-loss-only authorizations, proactively notify members and providers that coverage will end on September 30, 2026, and no claims will be reimbursed after that date for this indication.
03For Wegovy and Zepbound, verify the medical indication on each authorization; if not documented for cardiovascular risk reduction (Wegovy), MASH with F2-F3 fibrosis (Wegovy), or sleep apnea (Zepbound), end-date the authorization.
04For type 2 diabetes GLP-1 medications (Ozempic, Mounjaro, Trulicity, generic Victoza, Rybelsus, Exenatide), no action is required for existing authorizations—they remain in force.
05Update billing system rules and prior authorization templates to reflect that weight-loss indications are non-covered effective October 1, 2026.
06Implement workflow to flag any new prior authorization requests for GLP-1s submitted on or after October 1 for review against the updated 'Pharmacy Products Without Specific Criteria' MNG (to be posted October 1).
07For members under 21, ensure requests are reviewed for EPSDT compliance.
If missed: Failure to process these changes will result in claim denials and member confusion.
Original notice
Coverage of GLP-1s for Tufts Health RITogether members
point32health.org · Always check the source before changing claims.